Across the country, states are tackling rising budget deficits. And as economics correspondent Chris Farrell explains, health care is at the heart of federal and state deficits.

Not long ago, Arbidol was considered a nearly useless drug. Now, it's a best seller, and a symbol of Russia's efforts to build its pharmaceutical industry, at any cost.

American pharmaceutical companies want to build their sales in Russia. Russia is eager to let them so long as they build something else, too. Factories.

Wednesday brought an end to the long-awaited deal between French pharmaceutical company Sanofi-Aventis and the U.S. biotech firm Genzyme. Sanofi will buy Genzyme for at least $20.1 billion. But the number could go higher if Genzym's drugs-in-development succeed when they go to market, as Eve Troeh explains.